PO.ET07.02 · 实验与分子治疗

CellMiner Cross-Database (CellMinerCDB) for Exploration of Patient-Derived Cancer Cell Line Pharmacogenomics

海报缩略图:CellMiner Cross-Database (CellMinerCDB) for Exploration of Patient-Derived Cancer Cell Line Pharmacogenomics
编号 3138 展板 6 时间 4/20 02:00–05:00 区域 Section 18 主讲 Fathi Elloumi, PhD
分会场 Pharmacogenomics and Translational Biomarkers for Precision Cancer Therapy
查看完整资料 下载 PDF 登录后可访问当前开放资料 AACR 官方页面 ↗

作者与单位

Fathi Elloumi1, William C. Reinhold2, Sudhir Varma3, Yanghsin Wang1, Meric Kinali4, Yashuhiro Arakawa5, Yoshitaka Inoue6, Mirit Aladjem1, Yves Pommier1, Augustin Luna7

1National Cancer Institute, Bethesda, MD,2National Cancer Institute, Rockville, MD,3HiThru Analytics LLC, Princeton, NJ,4University of Massachusetts-Boston, Boston, MA,5Jikei University, Tokyo, Japan,6National Library of Medicine,, Bethesda, MD,7National Library of Medicine, Bethesda, MD

摘要 Abstract

CellMiner Cross-Database (CellMinerCDB) (https://discover.nci.nih.gov/cellminercdb/) is an established interactive application providing direct access and enabling exploration of cancer cell line pharmacogenomics without extensive programming experience. Data are compiled from many sources, including the National Cancer Institute (NCI), Broad Institute DepMap, Sanger/MGH GDSC, MD Anderson Cancer Center (MDACC) MCLP, and National Center for Advancing Translational Sciences (NCATS) cell line projects. In the version 2.2 update, our collection has expanded to pharmacogenomics data for 1,916 cancer cell lines and over 25,000 drugs. Drug screening data include many additional compounds for potential drug repurposing from the Broad PRISM, NCATS, and NCI. The user interface facilitates uncovering specific samples of interest and identifying drug and cell lines across databases. We also expanded the annotations for cross-referencing other databases and downloading our data for further cancer biology and drug discovery studies. Herein, we provide use cases for CellMinerCDB including (i) data reproducibility given overlaps of cell lines, genes, and drugs across databases; (ii) candidate biomarker discovery; and (iii) cross-dataset analyses.
利益披露 Disclosure
F. Elloumi, None.. S. Varma, None.. Y. Wang, None.. M. Kinali, None.. Y. Arakawa, None.. Y. Inoue, None.. Y. Pommier, None.. A. Luna, None.

在会议检索中打开